The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 13, 2015

Filed:

Aug. 01, 2008
Applicants:

Ian Armitage, Medford, MA (US);

Eric L. Elliott, Brighton, MA (US);

Marianne Langston, North Andover, MA (US);

Steven P. Langston, North Andover, MA (US);

Quentin J. Mccubbin, Belmont, MA (US);

Hirotake Mizutani, Cambridge, MA (US);

Matthew Stirling, Boston, MA (US);

Lei Zhu, Bedford, MA (US);

Inventors:

Ian Armitage, Medford, MA (US);

Eric L. Elliott, Brighton, MA (US);

Marianne Langston, North Andover, MA (US);

Steven P. Langston, North Andover, MA (US);

Quentin J. McCubbin, Belmont, MA (US);

Hirotake Mizutani, Cambridge, MA (US);

Matthew Stirling, Boston, MA (US);

Lei Zhu, Bedford, MA (US);

Assignee:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07C 219/24 (2006.01); C07D 241/50 (2006.01); C07D 211/96 (2006.01); C07D 295/22 (2006.01); C07C 217/52 (2006.01); C07D 471/08 (2006.01); C07C 215/44 (2006.01); C07D 213/89 (2006.01); C07D 239/30 (2006.01); C07C 211/35 (2006.01);
U.S. Cl.
CPC ...
C07C 217/52 (2013.01); C07C 219/24 (2013.01); C07D 241/50 (2013.01); C07D 211/96 (2013.01); C07D 295/22 (2013.01); C07D 471/08 (2013.01); C07D 487/04 (2013.01); C07C 2101/08 (2013.01); C07C 215/44 (2013.01); C07D 213/89 (2013.01);
Abstract

Disclosed are processes and synthetic intermediates for the synthesis of compounds of formula (V) wherein the variables have the definitions contained herein. Such compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.


Find Patent Forward Citations

Loading…